Back to search results

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Amandeep Salhotra) · asalhotra@coh.org · 626-218-2405
    Contact: Principal Investigator (Amandeep Salhotra)

  • Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

    Contact: Study coordinator (Abhay Singh, MD, MPH) · singha21@ccf.org · 866-320-4573
    Contact: Principal Investigator (Abhay Singh, MD, MPH)
Study leads

  • Amandeep Salhotra, MD

    Principal Investigator

    City of Hope Medical Center

View source on ClinicalTrials.gov(opens in a new tab)